Effect of Schistosoma mansoni infection and its treatment on antibody responses to measles catch-up immunisation in pre-school children: A randomised trial.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
25
08
2018
accepted:
14
01
2019
revised:
27
02
2019
pubmed:
15
2
2019
medline:
21
3
2019
entrez:
15
2
2019
Statut:
epublish
Résumé
Schistosoma infection is associated with immune modulation that can influence responses to non-schistosome antigens. Vaccine responses may be impaired in S. mansoni-infected individuals. We investigated effects of S. mansoni infection on responses to childhood measles catch-up immunisation and of praziquantel treatment on this outcome in a randomised trial. The Immune Modulation and Childhood Immunisation (IMoChI) study was based in Entebbe, Uganda. Children aged 3-5 years (193 S. mansoni-infected and 61 uninfected) were enrolled. Infected children were randomised in a 1:1:1 ratio to receive praziquantel 2 weeks before, at time of, or 1 week after, measles catch-up immunisation. Plasma anti-measles IgG was measured at enrolment, 1 week and 24 weeks after measles immunisation. Primary outcomes were IgG levels and percentage of participants with levels considered protective against measles. Anti-measles IgG levels increased following immunisation, but at 1 week post-immunisation S. mansoni-infected, compared to uninfected, children had lower levels of anti-measles IgG (adjusted geometric mean ratio (aGMR) 0.4 [95% CI 0.2-0.7]) and the percentage with protective antibody levels was also lower (adjusted odds ratio 0.1 [0-0.9]). Among S. mansoni-infected children, anti-measles IgG one week post-immunisation was higher among those treated with praziquantel than among those who were not yet treated (treatment before immunisation, aGMR 2.3 [1.5-4.8]; treatment at immunisation aGMR 1.8 [1.1-3.5]). At 24 weeks post-immunisation, IgG levels did not differ between the trial groups, but tended to be lower among previously-infected children who were still S mansoni stool-positive than among those who became stool-negative. Our findings suggest that S. mansoni infection among pre-school children is associated with a reduced antibody response to catch-up measles immunisation, and that praziquantel treatment improves the response. S. mansoni infection may contribute to impaired vaccine responses in endemic populations; effective schistosomiasis control may be beneficial for vaccine efficacy. This should be further explored. ISRCTN87107592.
Sections du résumé
BACKGROUND
Schistosoma infection is associated with immune modulation that can influence responses to non-schistosome antigens. Vaccine responses may be impaired in S. mansoni-infected individuals. We investigated effects of S. mansoni infection on responses to childhood measles catch-up immunisation and of praziquantel treatment on this outcome in a randomised trial.
METHODOLOGY
The Immune Modulation and Childhood Immunisation (IMoChI) study was based in Entebbe, Uganda. Children aged 3-5 years (193 S. mansoni-infected and 61 uninfected) were enrolled. Infected children were randomised in a 1:1:1 ratio to receive praziquantel 2 weeks before, at time of, or 1 week after, measles catch-up immunisation. Plasma anti-measles IgG was measured at enrolment, 1 week and 24 weeks after measles immunisation. Primary outcomes were IgG levels and percentage of participants with levels considered protective against measles.
RESULTS
Anti-measles IgG levels increased following immunisation, but at 1 week post-immunisation S. mansoni-infected, compared to uninfected, children had lower levels of anti-measles IgG (adjusted geometric mean ratio (aGMR) 0.4 [95% CI 0.2-0.7]) and the percentage with protective antibody levels was also lower (adjusted odds ratio 0.1 [0-0.9]). Among S. mansoni-infected children, anti-measles IgG one week post-immunisation was higher among those treated with praziquantel than among those who were not yet treated (treatment before immunisation, aGMR 2.3 [1.5-4.8]; treatment at immunisation aGMR 1.8 [1.1-3.5]). At 24 weeks post-immunisation, IgG levels did not differ between the trial groups, but tended to be lower among previously-infected children who were still S mansoni stool-positive than among those who became stool-negative.
CONCLUSIONS AND SIGNIFICANCE
Our findings suggest that S. mansoni infection among pre-school children is associated with a reduced antibody response to catch-up measles immunisation, and that praziquantel treatment improves the response. S. mansoni infection may contribute to impaired vaccine responses in endemic populations; effective schistosomiasis control may be beneficial for vaccine efficacy. This should be further explored.
TRIAL REGISTRATION
ISRCTN87107592.
Identifiants
pubmed: 30763405
doi: 10.1371/journal.pntd.0007157
pii: PNTD-D-18-01285
pmc: PMC6392333
doi:
Substances chimiques
Anthelmintics
0
Antibodies, Viral
0
Immunoglobulin G
0
Measles Vaccine
0
Praziquantel
6490C9U457
Banques de données
ISRCTN
['ISRCTN87107592']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007157Subventions
Organisme : Medical Research Council
ID : MC_UU_00027/5
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 084344
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K012126/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 095778
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Immunol. 1999 Jun 1;162(11):6843-8
pubmed: 10352306
Infect Immun. 1999 Nov;67(11):5951-7
pubmed: 10531253
Clin Exp Immunol. 2001 Feb;123(2):219-25
pubmed: 11207651
J Immunol. 2001 Oct 15;167(8):4293-302
pubmed: 11591752
Nat Rev Immunol. 2003 Sep;3(9):733-44
pubmed: 12949497
J Infect Dis. 1992 Aug;166(2):265-8
pubmed: 1386097
J Clin Lab Anal. 1992;6(6):417-22
pubmed: 1432369
Infect Immun. 2004 May;72(5):2598-604
pubmed: 15102768
Infect Immun. 2004 Jul;72(7):4023-30
pubmed: 15213147
J Immunol. 1992 May 15;148(10):3264-70
pubmed: 1533656
Immunol Rev. 2004 Oct;201:89-116
pubmed: 15361235
Vaccine. 1992;10(1):49-52
pubmed: 1539460
J Immunol. 2004 Dec 15;173(12):7454-61
pubmed: 15585871
Vaccine. 2006 May 8;24(19):4111-5
pubmed: 16554111
J Immunol. 2006 Jun 1;176(11):6918-27
pubmed: 16709852
Ann Trop Med Parasitol. 2006 Jun;100(4):315-26
pubmed: 16762112
Immunobiology. 2007;212(6):475-90
pubmed: 17544832
Rev Soc Bras Med Trop. 2007 Mar-Apr;40(2):147-51
pubmed: 17568879
Am J Trop Med Hyg. 2007 Oct;77(4):676-82
pubmed: 17978070
J Exp Med. 1991 Jan 1;173(1):159-66
pubmed: 1824635
Vaccine. 2008 Jul 23;26(31):3897-902
pubmed: 18554755
Immunol Lett. 2008 Aug 15;119(1-2):12-6
pubmed: 18585791
Am J Trop Med Hyg. 2008 Sep;79(3):331-7
pubmed: 18784223
Curr Top Microbiol Immunol. 2009;330:151-71
pubmed: 19203109
Mol Biochem Parasitol. 2009 Sep;167(1):1-11
pubmed: 19406170
PLoS Negl Trop Dis. 2009 May 26;3(5):e442
pubmed: 19478847
Geospat Health. 2009 Nov;4(1):39-53
pubmed: 19908189
Vaccine. 2010 Dec 16;29(2):247-55
pubmed: 21040693
PLoS Negl Trop Dis. 2011 Jan 04;5(1):e938
pubmed: 21245910
Am J Trop Med Hyg. 1990 May;42(5):449-52
pubmed: 2140243
Am J Trop Med Hyg. 1990 Nov;43(5):516-9
pubmed: 2146894
J Infect Dis. 2011 Jul;204 Suppl 1:S133-48
pubmed: 21666154
J Infect Dis. 2013 Jul;208(1):159-69
pubmed: 23045617
PLoS One. 2012;7(12):e51512
pubmed: 23272112
Trends Parasitol. 2013 Apr;29(4):197-205
pubmed: 23465781
PLoS Negl Trop Dis. 2013;7(3):e2136
pubmed: 23556020
BMC Public Health. 2013 Jul 01;13:619
pubmed: 23816281
J Clin Invest. 2014 Jul;124(7):3147-58
pubmed: 24911151
PLoS One. 2014 Nov 14;9(11):e112469
pubmed: 25398130
Trop Med Parasitol. 1989 Dec;40(4):445-53
pubmed: 2623427
PLoS Negl Trop Dis. 2015 Aug 20;9(8):e0003995
pubmed: 26291831
MBio. 2016 Aug 09;7(4):
pubmed: 27507822
PLoS Negl Trop Dis. 2016 Dec 7;10(12):e0005180
pubmed: 27926921
Wkly Epidemiol Rec. ;92(17):205-27
pubmed: 28459148
PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440
pubmed: 28472067
BMC Infect Dis. 2018 Jan 8;18(1):21
pubmed: 29310585
Am J Trop Med Hyg. 1987 May;36(3):549-53
pubmed: 2953263
BMC Infect Dis. 2018 Aug 20;18(1):412
pubmed: 30126362
Clin Infect Dis. 2018 Sep 8;:null
pubmed: 30202872
Rev Inst Med Trop Sao Paulo. 1972 Nov-Dec;14(6):397-400
pubmed: 4675644
Pediatrics. 1995 Jul;96(1 Pt 1):29-35
pubmed: 7596718
J Infect Dis. 1996 Jan;173(1):269-72
pubmed: 8537675
Rev Soc Bras Med Trop. 1996 Sep-Oct;29(5):441-5
pubmed: 8885672